Cancer prevention research (Philadelphia, Pa.) · 2026
Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыПоддержка правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morgan Douglas R, Dominguez Ricardo L, Norwood Dalton A, Montalvan-Sanchez Eleazar E, Piazuelo M Blanca, Rodriguez-Murillo Aida, Delgado Alberto G, Hernandez-Marrero Jessica, Gonzalez-Pons Maria, Beasley T Mark, Cruz-Correa Marcia, Wilson Keith T
Аннотация
UNLABELLED: Gastric adenocarcinoma is the fifth leading cause of global cancer mortality and a major health disparity in the United States. Effective chemoprevention strategies are limited for high-risk individuals with gastric premalignant conditions (GPMC). We conducted an NCI Division of Cancer Prevention-funded, double-blinded, phase IIa randomized, placebo-controlled trial evaluating eflornithine for chemoprevention in GPMC (NCT02794428). The study was executed in rural Honduras and Puerto Rico, regions with a high prevalence of Helicobacter pylori and gastric intestinal metaplasia (GIM), from September 2016 to December 2022. Eligible subjects (ages 30-69; H. pylori-positive or H. pylori-negative) were randomized 1:1 to receive 500 mg/day eflornithine or placebo for 18 months. Upper endoscopy was performed at baseline, 6, 18, and 24 months. H. pylori-positive patients were offered antibiotic treatment at 6 months. A total of 211 patients were screened, and 91 were randomized (45 to eflornithine and 46 to placebo). The mean age was 45.2 years (SD 8.8), and 74% were female. At baseline, 46% and 54% had gastric atrophy and GIM, respectively. Eighty percent were H. pylori-positive. Follow-up completion rates were 78 patients (6 months), 69 patients (18 months), and 55 patients (24 months). Eflornithine was well tolerated, with fewer grade 1 to 2 adverse events in the eflornithine group (81 vs. 108, placebo). No significant histology score differences were observed. A significant reduction in DNA damage (pH2AX-positive cells) was observed in the 24-month versus 18-month assessments (P = 0.012). Eflornithine was safe and well tolerated in patients with GPMC. The findings suggest that eflornithine reduces long-term DNA damage, supporting further trials to refine treatment duration and patient selection.
PREVENTION RELEVANCE: Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation-alone or combined with H. pylori eradication-as a strategy to interrupt gastric carcinogenesis in high-risk populations. See related Spotlight, p. 387 See related article by Gonzalez-Pons et al., p. 403.
PREVENTION RELEVANCE: Individuals with GPMCs have limited chemoprevention options despite substantial gastric cancer risk. This phase IIa randomized trial shows that eflornithine is safe and reduces long-term DNA damage, supporting its further evaluation-alone or combined with H. pylori eradication-as a strategy to interrupt gastric carcinogenesis in high-risk populations. See related Spotlight, p. 387 See related article by Gonzalez-Pons et al., p. 403.